GEN Exclusives

More »

GEN News Highlights

More »
Apr 19, 2007

Novacea Snags Rights to Oncology Agent from Kudos and BTG

  • Novacea gained access to Kudos Pharmaceuticals’ anticancer agent. AQ4N (banoxantrone) is currently in Phase I evalution in patients with advanced oesophageal cancer.

    "The extensive preclinical and clinical data generated to date gives us confidence in the significant opportunity AQ4N presents as an anticancer agent in multiple tumor types and hematological malignancies," states John P. Walker, chairman and interim CEO of Novacea.

    As part of the agreement, Novacea will acquire an exclusive license and worldwide development and commercialization rights for the candidate. Kudos anticipates it will complete patient recruitment for its ongoing Phase I trials with AQ4N around the middle of 2007.

    Kudos obtained a worldwide license for AQ4N from BTG in March 2002 and subsequently licensed the North American rights to Novacea in December 2003.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »